Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Maintenance in Advanced Esophageal Carcinoma
NCT02011594Phase 2Withdrawn
- Sponsor
- Zhejiang University
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang University. Planned start Jan 2014; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02011594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011594.